Abstract 1579P
Background
Worldwide, AYA care for patients < 25 years is mostly delivered by paediatric oncologists. For the whole range of patients at AYA age (15- 39 years) there is a need for AYA care in adult oncology practices. In 2014, a national AYA network with central coordination, started in the Netherlands (NL) in 7 university medical centres and a cancer centre, with the aim to extend to a nationwide network in the adult oncology environment. This network, co-designed by healthcare professionals (HCPs), patients and caregivers, has evolved towards a data driven learning healthcare system and may be a model for other countries as well.
Methods
From its start, with very limited resources, annual plans were made with lean deliverables, topics on AYA care domains were addressed, (mandatory) teaching modules for HCPs have been developed, and AYA research projects were written with the aim to constantly feed data into the educational and care initiatives of the network.
Results
In ten years, the number of hospitals delivering AYA care has expanded to 75; since 2024 AYA care and network-management is reimbursed by healthcare insurance companies. Research projects have been awarded from the Dutch Cancer Society, Dutch Scientific Council and EU Horizon program. COMPRAYA – a prospective study to collect clinical, biological and psychosocial data, GENAYA - a collection of whole genome sequencing data, INVAYA and CORDAYA –research projects for AYAs with an uncertain or poor prognosis and SURVAYA investigating AYAs 5-20 years after diagnosis, all generate data to constantly improve AYA care. Our awarded EU project STRONG AYA, with federated data collection running in NL, UK, France, Poland and Italy will generate data for individual countries and will ensure benchmarking to improve AYA care at pan-European level. Results of projects are evaluated regularly by master and PhD students with medical, psychosocial and econometry background and postdoctoral researchers, supervised by the core team. Teaching modules are adapted and developed based on the obtained data.
Conclusions
The model of a learning AYA-healthcare system enables collaborative (inter)national data driven initiatives, which has the advantage to improve AYA care at an (inter)national and local level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10